ArticleTherapeutic advances in chronic disease2023

Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn's disease cohort with penetrating disease, -ostomies and sarcopenia.

Saskia Inniss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.